You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石药业(02616.HK):在研抗肿瘤药客观缓解率达77.8%
阿思达克 09-20 09:10

基石药业(02616.HK)公布,在研产品抗PD-L1抗体CS1001在一项食管鳞癌Ib期研究数据显示,在晚期食管鳞癌患者中,CS1001联合CF化疗方案作为一线治疗表现出良好的抗肿瘤活性,客观缓解率达到77.8%,且缓解可持续,同时总体安全性及耐受性良好。

公司董事长、执行董事兼首席执行官江宁军表示,CS1001是一款专门针对多个中国高发癌种开发的在研创新肿瘤免疫治疗候选药物,食管鳞癌於中国属高发恶性肿瘤,期待产品在之後的临床试验中取得更出色的表现,早日成为食管鳞癌患者新的治疗选择。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account